Cencora Beheer

Beheer criteriumcontroles 2/4

De CEO Cencora is Bob Mauch, benoemd in Oct2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.70M, bestaande uit 12.7% salaris en 87.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.027% van de aandelen van het bedrijf, ter waarde $ 13.00M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 9.5 jaar.

Belangrijke informatie

Bob Mauch

Algemeen directeur

US$7.7m

Totale compensatie

Percentage CEO-salaris	12.7%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bob Mauch's beloning veranderd ten opzichte van Cencora's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

Compensatie versus markt: De totale vergoeding ($USD 7.70M ) Bob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.77M ).

Compensatie versus inkomsten: De beloning van Bob is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Bob Mauch (57 yo)

2.1yrs

Tenure

US$7,697,850

Compensatie

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.19% $ 92.7m
Robert Mauch	President	2.1yrs	US$7.70m	0.027% $ 13.0m
James Cleary	Executive VP & CFO	6yrs	US$5.45m	0.070% $ 33.9m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.2yrs	US$4.03m	0.0096% $ 4.6m
Lazarus Krikorian	Senior VP	12.8yrs	geen gegevens	0.012% $ 5.9m
Pawan Verma	Executive VP	less than a year	geen gegevens	geen gegevens
Bennett Murphy	Senior Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	geen gegevens	geen gegevens
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.011% $ 5.4m
Richard Tremonte	EVP & President of U.S. Pharmaceuticals	less than a year	geen gegevens	geen gegevens
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	geen gegevens	geen gegevens
Juan Guerra	EVP & President of International Business Group	less than a year	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HF3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.19% $ 92.7m
Robert Mauch	President	less than a year	US$7.70m	0.027% $ 13.0m
Lauren Tyler	Independent Director	1.1yrs	geen gegevens	geen gegevens
Richard Gochnauer	Independent Director	16.2yrs	US$300.10k	0.011% $ 5.5m
Mark M. Durcan	Lead Independent Director	9.2yrs	US$380.05k	0.010% $ 4.8m
Lon Greenberg	Independent Director	11.5yrs	US$332.60k	0.0057% $ 2.8m
Kathleen Hyle	Independent Director	14.5yrs	US$320.10k	0.011% $ 5.2m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0052% $ 2.5m
Ornella Barra	Director	9.8yrs	geen gegevens	geen gegevens
Henry McGee	Independent Director	20yrs	US$320.10k	0.0077% $ 3.7m
Lorence Kim	Independent director	2.1yrs	US$397.33k	0.000090% $ 43.4k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% $ 386.1k

9.5yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HF3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Cencora Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Executive Chairman recently sold US$12m worth of stock

Cencora, Inc. Announces Management Appointments

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Recent updates

Executive Chairman recently sold US$12m worth of stock

Fourth quarter dividend increased to US$0.55

Cencora, Inc. Declares Quarterly Dividend, Payable on November 29, 2024

Full year 2024 earnings released: EPS: US$7.60 (vs US$8.62 in FY 2023)

Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion.

Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion.

Cencora, Inc. Announces Management Appointments

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings released: EPS: US$2.44 (vs US$2.37 in 3Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings released: EPS: US$2.11 (vs US$2.15 in 2Q 2023)

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Chairman recently sold US$8.7m worth of stock

Now 20% undervalued

Insider recently sold US$2.0m worth of stock

Now 21% undervalued

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Now 20% undervalued

Now 20% undervalued after recent price drop

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Now 20% undervalued

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold US$731k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Now 21% undervalued

Insider recently sold US$301k worth of stock

Senior VP recently sold US$890k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold US$137k worth of stock

Executive VP & Chief Strategy Officer recently sold US$501k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Third quarter 2022 earnings released: EPS: US$1.95 (vs US$1.42 in 3Q 2021)

AmerisourceBergen Corporation Reports Goodwill Impairment for the Three Months Ended June 30, 2022

AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

AmerisourceBergen Corporation to Report Q3, 2022 Results on Aug 03, 2022

AmerisourceBergen Corporation (NYSE:ABC) announces an Equity Buyback for $1,000 million worth of its shares.